Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Blandine Avignon"'
Autor:
Thomas D. Lewin, Blandine Avignon, Alessio Tovaglieri, Lauriane Cabon, Nikolche Gjorevski, Lucy G. Hutchinson
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Cancer immunotherapy often involves the use of engineered molecules to selectively bind and activate T cells located within tumour tissue. Fundamental to the success of such treatments is the presence or recruitment of T cells localised within the tu
Externí odkaz:
https://doaj.org/article/fd3e59da22e0471e9e57da377981c377
Autor:
Sabine Sewing, Marcel Gubler, Régine Gérard, Blandine Avignon, Yasmin Mueller, Annamaria Braendli-Baiocco, Marielle Odin, Annie Moisan
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 14, Iss , Pp 67-79 (2019)
Targeted delivery of antisense oligonucleotide (AON) drugs is a promising strategy to increase their concentration in the desired tissues and cell types while reducing access to other organs. Conjugation of AONs to N-acetylgalactosamine (GalNAc) has
Externí odkaz:
https://doaj.org/article/2372d539f88947098a3a24ddd5408f46
Autor:
Annie Moisan, Marcel Gubler, Jitao David Zhang, Yann Tessier, Kamille Dumong Erichsen, Sabine Sewing, Régine Gérard, Blandine Avignon, Sylwia Huber, Fethallah Benmansour, Xing Chen, Roberto Villaseñor, Annamaria Braendli-Baiocco, Matthias Festag, Andreas Maunz, Thomas Singer, Franz Schuler, Adrian B. Roth
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 6, Iss , Pp 89-105 (2017)
Antisense oligonucleotide (AON) therapeutics offer new avenues to pursue clinically relevant targets inaccessible with other technologies. Advances in improving AON affinity and stability by incorporation of high affinity nucleotides, such as locked
Externí odkaz:
https://doaj.org/article/6a19a17eb817471d91d25a02041685db
Autor:
Céline Adessi, Martin Weisser, Andreas Schneeweiss, Max Hasmann, Georgina Meneses-Lorente, Christine McIntyre, Fethallah Benmansour, Régine Gérard, Blandine Avignon, Sabine Wilson, Sven Kronenberg, Wolfgang Jacob, Francesca Michielin, Annie Moisan
1. Supplementary Figure 1. Illustration of tubes area detection as rectangles based on the bright field channel. 2. Supplementary Figure 2. Diarrhea severity during combination treatment with lumretuzumab (RO5479599), pertuzumab and paclitaxel in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54db68e27685812d3371a76fa3b6a2f4
https://doi.org/10.1158/1535-7163.22505418
https://doi.org/10.1158/1535-7163.22505418
Data from Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy
Autor:
Céline Adessi, Martin Weisser, Andreas Schneeweiss, Max Hasmann, Georgina Meneses-Lorente, Christine McIntyre, Fethallah Benmansour, Régine Gérard, Blandine Avignon, Sabine Wilson, Sven Kronenberg, Wolfgang Jacob, Francesca Michielin, Annie Moisan
Combination of targeted therapies is expected to provide superior efficacy in the treatment of cancer either by enhanced antitumor activity or by preventing or delaying the development of resistance. Common challenges in developing combination therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf3ecdffdb68901e0ce6f6d3303c1fb6
https://doi.org/10.1158/1535-7163.c.6538053.v1
https://doi.org/10.1158/1535-7163.c.6538053.v1
Autor:
Thomas D, Lewin, Blandine, Avignon, Alessio, Tovaglieri, Lauriane, Cabon, Nikolche, Gjorevski, Lucy G, Hutchinson
Publikováno v:
Frontiers in pharmacology. 13
Cancer immunotherapy often involves the use of engineered molecules to selectively bind and activate T cells located within tumour tissue. Fundamental to the success of such treatments is the presence or recruitment of T cells localised within the tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::494c6e725ea0d4522920602b596abf4d
https://pubmed.ncbi.nlm.nih.gov/35586042
https://pubmed.ncbi.nlm.nih.gov/35586042
Autor:
Annie Moisan, Adrian Roth, Nikolce Gjorevski, Blandine Avignon, Lauriane Cabon, Régine Gérard, Michael Bscheider
Publikováno v:
Lab on a chip. 20(18)
The multiphasic etiology of tissue inflammation and the fundamental immunological differences between species render inflammatory pathologies difficult to recapitulate in animal models, and account for the paucity of therapies that are successfully t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d78c4a3cd41e25c0c751344fd72ab1fe
https://pubmed.ncbi.nlm.nih.gov/32761043
https://pubmed.ncbi.nlm.nih.gov/32761043
Autor:
Sabine Wilson, Andreas Schneeweiss, Annie Moisan, Francesca Michielin, Martin Weisser, Christine McIntyre, Max Hasmann, Blandine Avignon, Fethallah Benmansour, Régine Gérard, Celine Adessi, Georgina Meneses-Lorente, Wolfgang Jacob, Sven Kronenberg
Publikováno v:
Molecular Cancer Therapeutics. 17:1464-1474
Combination of targeted therapies is expected to provide superior efficacy in the treatment of cancer either by enhanced antitumor activity or by preventing or delaying the development of resistance. Common challenges in developing combination therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b7a729ef461c8a51425a55926a85e52
https://doi.org/10.1158/1535-7163.mct-17-1268
https://doi.org/10.1158/1535-7163.mct-17-1268
Autor:
Marcel Gubler, Kamille Dumong Erichsen, Adrian Roth, Régine Gérard, Fethallah Benmansour, Xing Chen, Jitao David Zhang, Sylwia Huber, Matthias Festag, Yann Tessier, Roberto Villaseñor, Sabine Sewing, Blandine Avignon, Thomas Singer, Andreas Maunz, Franz Schuler, Annie Moisan, Annamaria Braendli-Baiocco
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 6, Iss, Pp 89-105 (2017)
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids
Antisense oligonucleotide (AON) therapeutics offer new avenues to pursue clinically relevant targets inaccessible with other technologies. Advances in improving AON affinity and stability by incorporation of high affinity nucleotides, such as locked
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b94950840f7bc75e2af78fbe25415b4
https://doi.org/10.1016/j.omtn.2016.11.006
https://doi.org/10.1016/j.omtn.2016.11.006